Skip to main content
. Author manuscript; available in PMC: 2016 Nov 28.
Published in final edited form as: Oral Oncol. 2014 Aug 11;50(10):947–955. doi: 10.1016/j.oraloncology.2014.07.001

Table 2.

Characteristics of 5FU/carboplatin versus cetuximab patients.

Characteristic Drug P value

5FU/carboplatin (n = 52) Cetuximab (n = 49)
n (%) n (%)
Age .03
 <71 41 (78.8) 29 (59.2)
 ≥71 11 (21.2) 20 (40.8)
Race .69
 Caucasian 45 (86.5) 41 (83.7)
 Non-Caucasian 7 (13.5) 8 (16.3)
Sex .52
 Male 43 (82.7) 38 (77.6)
 Female 9 (17.3) 11 (22.4)
Primary site .68
 Oropharynx 38 (73.1) 34 (69.4)
 Hypopharynx/larynx 14 (26.9) 15 (30.6)
T classification .57
 T1 9 (17.3) 9 (18.4)
 T2 12 (23.1) 17 (34.7)
 T3 17 (32.7) 12 (24.5)
 T4 14 (26.9) 11 (22.4)
N classification .61
 N0 3 (5.8) 9 (12.2)
 N1 14 (26.9) 11 (22.5)
 N2 34 (65.4) 30 (61.2)
 N3 1 (1.9) 2 (4.1)
Overall stage .40
 II 0 (0) 0 (0)
 III 13 (25.0) 16 (32.7)
 IV 39 (75.0) 33 (67.3)
Alcohol history .10
 Low/mild 17 (32.7) 24 (49.0)
 Moderate/heavy 35 (67.3) 25 (51.0)
>10 pack-yr tobacco .39
 No 19 (36.5) 22 (44.9)
 Yes 33 (63.5) 27 (55.1)
KPS .16
 NA 1 (1.9) 0 (0)
 >80 37 (71.2) 29 (59.2)
 ≤80 14 (26.9) 20 (40.8)
Cr clearancea .27
 ≥60 42 (80.8) 35 (71.4)
 <60 10 (19.2) 14 (28.6)
Charlson index .04
 0 24 (46.2) 29 (59.2)
 1 9 (17.3) 13 (26.5)
 ≥2 19 (36.5) 7 (14.3)
Pre-RT trach 1.00
 No 47 (90.4) 45 (91.8)
 Yes 5 (9.6) 4 (8.2)
Neck dissection .20
 No 51 (98.1) 45 (91.8)
 Yes 1 (1.9) 4 (8.2)
Switched chemotherapy
 No 46 (88.5) 49 (100.0) .03
 Yes 6 (11.5) 0 (0)
Radiation length (days), median (range) 47 (42–58) 46 (6–70) .34

Abbreviations: RT = radiation therapy; KPS = Karnofsky performance status; Trach = tracheostomy; Cr = creatinine.

a

Calculated using Cockcroft-Gault formula.